Financing Deal of the Year’ award 2021 for Amphista Therapeutics

Published on 18 January 2022

Amphista Therapeutics, the spin out company from the lab of Professor Alessio Ciulli, was awarded the ‘Financing Deal of the Year’ award 2021 at the Scrip Awards last month. This was in recognition of their $53M Series B funding.

On this page

The annual Scrips Awards applaud the essential role that the pharmaceutical, biotech and other allied industries play in improving healthcare. The awards span the entire range of industry activities, from new drug launches and clinical trials, to innovative deals, outsourcing and fundraising.

Professor Iain Gillespie, Principal and Vice-Chancellor said, “This recognition reflects the incredible work the Amphista team has put in and the progress achieved over the past year, resulting in an oversubscribed $53M Series B funding round, which has helped Amphista advance their next-generation targeted protein degradation assets. This is a prestigious accolade for us all in Dundee, where the company scientific foundations were built. It is an outstanding example of just how great an entrepreneurial and translational impact our research can have. Congratulations to Alessio and the team at Amphista.”

About Amphista

Amphista is a next generation TPD company working to advance a portfolio of innovative therapeutic candidates to clinical stage research and commercialization. The company’s Eclipsys™ Drug Development Platform is enabling development of novel protein degrading therapeutics with superior levels of efficacy and broad therapeutic applicability. A Approaches in drug development at Amphista are designed to improve the ability of TPD medicines to modulate drug targets and treat disease using synthetic small molecule degraders.